Advancing Tarlatamab for Small Cell Lung Cancer...

By HEOR Staff Writer

March 30, 2026

New Treatment Option for Relapsed Extensive-Stage Small Cell Lung Cancer Tarlatamab small cell lung therapy has received a positive opinion from the European Medicines Agency (EMA) for marketing authorisation. The bispec...
FDA Approves Once-Weekly Basal Insulin Awiqli® for Type 2 Diabetes Management
Inflation Reduction Act Impact on Clinical Trial Investment Trends
EU Alzheimer Approval Challenges: Anavex Withdraws Blarcamesine Application A...
South Africa Health Reform: Revitalizing the Crisis-Stricken Sector
NICE Pembrolizumab Recommendation for Locally Advanced Head and Neck Cancer T...
PEPFAR TB Impact: Averting Millions of Cases and Deaths Among HIV Patients
Vitamin B6 Depletion Risk in Carbidopa/Levodopa Therapy and Seizure Implications
Advancing Collaborative TB Innovation to Tackle Drug Resistance
Citation Analysis of Real-World Evidence in Medicare Drug Price Negotiations
Serplulimab Lung Cancer Treatment: Evaluation of Clinical and Economic Impact...
Cost-Effectiveness of T1D Screening Effectiveness in Canadian Children
Novartis Acquires Mutant-Selective PI3Kα Inhibitor to Enhance Breast Cancer T...